Payment overview · 2025
General Payments
$1,564.09
84 reported records · 21 companies
Healthcare provider profile · identity verified
Hashim Syed Raza, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · SAINT LOUIS, MO · NPI 1891840237
Verified facts
What the public records show
CMS Open Payments records show Hashim Syed Raza, M.D. received $1,564.09 in general payments during 2025 across 84 reported records.
ABBVIE INC. accounted for 38.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 40 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abrysvo, Eliquis, Linzess, Mounjaro, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 85 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 277 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $595.52 | 38.1% | 27 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $155.37 | 9.9% | 9 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $143.39 | 9.2% | 11 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $137.12 | 8.8% | 9 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $71.15 | 4.5% | 4 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $51.91 | 3.3% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $47.21 | 3.0% | 3 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$43.98 | 2.8% | 2 | 2025 |
| Tonix Medicines, Inc. | Unresolved — no canonical attribution shown | $39.16 | 2.5% | 2 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $32.63 | 2.1% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $31.51 | 2.0% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $29.90 | 1.9% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $29.02 | 1.9% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $25.66 | 1.6% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $21.90 | 1.4% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $21.56 | 1.4% | 1 | 2025 |
| KYOWA KIRIN, INC. | Unresolved — no canonical attribution shown | $21.38 | 1.4% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $20.39 | 1.3% | 1 | 2025 |
| PROTEGA PHARMACEUTIALS INC | Unresolved — no canonical attribution shown | $18.15 | 1.2% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $14.63 | 0.9% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $12.55 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,564.09 | 84 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $327.05 | 12 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $267.21 | 12 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $155.37 | 9 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $155.37 | 9 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $133.43 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $93.08 | 6 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $83.35 | 4 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $71.15 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $68.78 | 4 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $56.05 | 6 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $53.14 | 3 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $53.14 | 3 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $53.14 | 3 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $51.91 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $44.04 | 3 | 2025 |
Source payment records
|
|||||
| INCEPTIV Normalized: inceptiv |
Device | Medtronic, Inc. | $43.98 | 2 | 2025 |
Source payment records
|
|||||
| TONMYA Normalized: tonmya |
Drug | Tonix Medicines, Inc. | $39.16 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $38.61 | 3 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $34.20 | 2 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $32.63 | 1 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $29.90 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $29.02 | 2 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $29.02 | 2 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $27.91 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $25.66 | 1 | 2025 |
Source payment records
|
|||||
| VIBERZI Normalized: viberzi |
Drug | ABBVIE INC. | $22.11 | 1 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $21.90 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $21.56 | 1 | 2025 |
Source payment records
|
|||||
| CRYSVITA Normalized: crysvita |
Drug | KYOWA KIRIN, INC. | $21.38 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $20.39 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $19.30 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $19.30 | 1 | 2025 |
Source payment records
|
|||||
| ROXYBOND Normalized: roxybond |
Drug | PROTEGA PHARMACEUTIALS INC | $18.15 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $17.44 | 3 | 2025 |
Source payment records
|
|||||
| SAPHNELO Normalized: saphnelo |
Biological | AstraZeneca Pharmaceuticals LP | $17.36 | 1 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $16.40 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $14.63 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $14.38 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $14.15 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $12.55 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABRYSVO abrysvo |
2025 | Abrysvo | 2024 | 13 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 277 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 40 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 75 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
85 | 24 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
38 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
68 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
54 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
75 | 15 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
13 | 13 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
277 | 61 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
57 | 55 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 953 | 269 |
| Amlodipine Besylate | Amlodipine Besylate | 882 | 230 |
| Levothyroxine Sodium | Levothyroxine Sodium | 658 | 169 |
| Losartan Potassium | Losartan Potassium | 605 | 158 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 597 | 173 |
| Alprazolam | Alprazolam | 513 | 115 |
| Lisinopril | Lisinopril | 499 | 144 |
| Omeprazole | Omeprazole | 450 | 140 |
| Metoprolol Succinate | Metoprolol Succinate | 363 | 95 |
| Donepezil Hcl | Donepezil Hcl | 362 | 98 |
| Pravastatin Sodium | Pravastatin Sodium | 358 | 97 |
| Metformin Hcl | Metformin Hcl | 355 | 97 |
| Zolpidem Tartrate | Zolpidem Tartrate | 308 | 53 |
| Gabapentin | Gabapentin | 297 | 77 |
| Hydrochlorothiazide | Hydrochlorothiazide | 291 | 81 |
| Pantoprazole Sodium | Pantoprazole Sodium | 291 | 73 |
| Tamsulosin Hcl | Tamsulosin Hcl | 288 | 80 |
| Eliquis | Apixaban | 277 | 61 |
| Simvastatin | Simvastatin | 268 | 74 |
| Tramadol Hcl | Tramadol Hcl | 264 | 65 |
| Sertraline Hcl | Sertraline Hcl | 252 | 71 |
| Trazodone Hcl | Trazodone Hcl | 249 | 61 |
| Metoprolol Tartrate | Metoprolol Tartrate | 244 | 60 |
| Escitalopram Oxalate | Escitalopram Oxalate | 242 | 60 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 239 | 238 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 238 | 61 |
| Mirtazapine | Mirtazapine | 214 | 64 |
| Allopurinol | Allopurinol | 202 | 52 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 197 | 55 |
| Meloxicam | Meloxicam | 192 | 59 |
| Furosemide | Furosemide | 182 | 65 |
| Memantine Hcl | Memantine Hcl | 180 | 49 |
| Carvedilol | Carvedilol | 158 | 43 |
| Atenolol | Atenolol | 150 | 40 |
| Potassium Chloride | Potassium Chloride | 147 | 48 |
| Clopidogrel | Clopidogrel Bisulfate | 133 | 37 |
| Montelukast Sodium | Montelukast Sodium | 131 | 36 |
| Ezetimibe | Ezetimibe | 130 | 34 |
| Finasteride | Finasteride | 125 | 35 |
| Duloxetine Hcl | Duloxetine Hcl | 124 | 27 |
| Metformin Hcl Er | Metformin Hcl | 113 | 32 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 106 | 36 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 102 | 41 |
| Lorazepam | Lorazepam | 97 | 21 |
| Xarelto | Rivaroxaban | 96 | 20 |
| Citalopram Hbr | Citalopram Hydrobromide | 91 | 23 |
| Celecoxib | Celecoxib | 85 | 24 |
| Synthroid | Levothyroxine Sodium | 85 | 24 |
| Fluticasone Propionate | Fluticasone Propionate | 79 | 34 |
| Clonazepam | Clonazepam | 78 | 12 |
| Irbesartan | Irbesartan | 75 | 19 |
| Ozempic | Semaglutide | 75 | 15 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 72 | 21 |
| Famotidine | Famotidine | 70 | 21 |
| Fluoxetine Hcl | Fluoxetine Hcl | 70 | 17 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 70 | 17 |
| Jardiance | Empagliflozin | 68 | 17 |
| Azithromycin | Azithromycin | 63 | 53 |
| Glimepiride | Glimepiride | 61 | 19 |
| Ropinirole Hcl | Ropinirole Hcl | 58 | 15 |
| Paxlovid | Nirmatrelvir/Ritonavir | 57 | 55 |
| Spironolactone | Spironolactone | 55 | 14 |
| Amoxicillin | Amoxicillin | 54 | 36 |
| Methylprednisolone | Methylprednisolone | 54 | 49 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 54 | 18 |
| Trulicity | Dulaglutide | 54 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 54 | 14 |
| Hydralazine Hcl | Hydralazine Hcl | 53 | 14 |
| Ipratropium Bromide | Ipratropium Bromide | 53 | 17 |
| Valacyclovir | Valacyclovir Hcl | 53 | 20 |
| Tizanidine Hcl | Tizanidine Hcl | 50 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 49 | 13 |
| Buspirone Hcl | Buspirone Hcl | 45 | 15 |
| Doxazosin Mesylate | Doxazosin Mesylate | 45 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 44 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 44 | 26 |
| Nebivolol Hcl | Nebivolol Hcl | 44 | 13 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 43 | suppressed |
| Glipizide Er | Glipizide | 43 | 11 |
| Oxycodone Hcl | Oxycodone Hcl | 41 | suppressed |
| Bupropion Xl | Bupropion Hcl | 40 | 15 |
| Mounjaro | Tirzepatide | 40 | suppressed |
| Myrbetriq | Mirabegron | 40 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 39 | 13 |
| Temazepam | Temazepam | 39 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 38 | 12 |
| Glipizide | Glipizide | 38 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 38 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 38 | 34 |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 36 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 35 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 35 | suppressed |
| Diazepam | Diazepam | 34 | 13 |
| Telmisartan | Telmisartan | 34 | suppressed |
| Ursodiol | Ursodiol | 33 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 33 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 32 | 11 |
| Indapamide | Indapamide | 32 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 32 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 31 | suppressed |
| Ibuprofen | Ibuprofen | 31 | 12 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 30 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 30 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Lovastatin | Lovastatin | 30 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 30 | suppressed |
| Pregabalin | Pregabalin | 30 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 30 | suppressed |
| Lamotrigine | Lamotrigine | 29 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 29 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 29 | suppressed |
| Ramipril | Ramipril | 29 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 29 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 28 | 26 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 28 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 28 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 27 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 27 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 27 | suppressed |
| Verapamil Er | Verapamil Hcl | 26 | suppressed |
| Fenofibrate | Fenofibrate | 25 | suppressed |
| Ondansetron Odt | Ondansetron | 25 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 24 | suppressed |
| Ketoconazole | Ketoconazole | 24 | 13 |
| Prednisone | Prednisone | 24 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 24 | suppressed |
| Levetiracetam | Levetiracetam | 23 | suppressed |
| Primidone | Primidone | 23 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 22 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 22 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 22 | suppressed |
| Testosterone | Testosterone | 22 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 21 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 21 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 21 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 21 | suppressed |
| Valsartan | Valsartan | 21 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 20 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 20 | 11 |
| Breo Ellipta | Fluticasone/Vilanterol | 19 | suppressed |
| Chlorthalidone | Chlorthalidone | 19 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 18 | 17 |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 18 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 18 | suppressed |
| Cephalexin | Cephalexin | 17 | 16 |
| Crestor | Rosuvastatin Calcium | 17 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 17 | suppressed |
| Estradiol | Estradiol | 17 | suppressed |
| Januvia | Sitagliptin Phosphate | 17 | suppressed |
| Linzess | Linaclotide | 17 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 17 | suppressed |
| Latanoprost | Latanoprost | 16 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 16 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 16 | suppressed |
| Aripiprazole | Aripiprazole | 15 | suppressed |
| Dutasteride | Dutasteride | 15 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 15 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Combigan | Brimonidine Tartrate/Timolol | 14 | suppressed |
| Dofetilide | Dofetilide | 14 | suppressed |
| Edarbi | Azilsartan Medoxomil | 14 | suppressed |
| Lansoprazole | Lansoprazole | 14 | suppressed |
| Loperamide | Loperamide Hcl | 14 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 14 | suppressed |
| Oxycontin | Oxycodone Hcl | 14 | suppressed |
| Rivastigmine | Rivastigmine | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Topiramate | Topiramate | 14 | suppressed |
| Torsemide | Torsemide | 14 | suppressed |
| Tradjenta | Linagliptin | 14 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 13 | 13 |
| Humalog Kwikpen U-200 | Insulin Lispro | 13 | suppressed |
| Lidocaine | Lidocaine | 13 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 13 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Dextroamphetamine Sulfate | Dextroamphetamine Sulfate | 12 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 12 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Nifedipine Er | Nifedipine | 12 | suppressed |
| Prevacid | Lansoprazole | 12 | suppressed |
| Rybelsus | Semaglutide | 12 | suppressed |
| Vyzulta | Latanoprostene Bunod | 12 | suppressed |
| Cyclosporine | Cyclosporine | 11 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 11 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 11 | suppressed |
| Repatha Syringe | Evolocumab | 11 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,564.09 · 84 records | ABBVIE INC. | ABRYSVO, AIRSUPRA, CAPVAXIVE, COMIRNATY, CREON, CRYSVITA, Cologuard Collection Kit, ELIQUIS, ENTRESTO, EVENITY, GARDASIL 9, INCEPTIV, JOURNAVX, KRYSTEXXA, Kerendia, LEQVIO, LINZESS, MOUNJARO, NURTEC ODT, Ozempic, PREVNAR 20, PROLIA, QULIPTA, ROXYBOND, Rybelsus, SAPHNELO, Symbravo, TONMYA, TZIELD, Tymlos, UBRELVY, VIBERZI, VOQUEZNA, VRAYLAR, VYEPTI, VYNDAQEL, Wegovy, XIFAXAN, ZAVZPRET, ZEPBOUND | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abrysvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error